Tiazac (diltiazem hydrochloride)

Company
Forest Laboratories

Approval Status
Approved February 1998

Treatment for
chronic stable angina

Possible similar drugs
Tiazac; Tiazac

Areas
Cardiovascular / Cardiology

Tiazac (diltiazem HCl) has been approved for the treatment of chronic stable angina. Tiazac was previously approved for the treatment of hypertension. Tiazac, a once-daily calcium channel blocker, has been proven highly effective in important angina efficacy parameters; it significantly reduces both angina attack rates and nitroglycerin consumption. Tiazac's central effects and peripheral vasodilating action balances oxygen supply and demand producing significantly greater increases in total duration of exercise compared to placebo. Additionally Tiazac effectively reduces blood pressure of hypertensive patients over the 24-hour dosing interval with a side-effect profile comparable to placebo, even when dosed up to 360 mg.

Tiazac has been shown to significantly reduce both angina attack rates and nitroglycerin consumption. Tiazac's central effects and peripheral vasodilating action balanced oxygen supply and demand producing significantly greater increases in total duration of exercise compared to placebo. Additionally, Tiazac effectively reduced blood pressure of hypertensive patients over a 24-hour dosing interval.

Side Effects: The side-effect profile is comparable to placebo, even when dosed up to 360 mg.

Tiazac (diltiazem HCl) is a once-daily calcium channel blocker.

Tiazac (diltiazem hydrochloride) Drug Information

The Tiazac (diltiazem hydrochloride) drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top